Saptak Chem &

Which are the latest news on Saptak Chem &?

What does Saptak Chem & do?

Saptak Chem and Business Ltd, formerly Munak Chemicals Limited, trades in agricultural produce and chemicals. As of March 2026, it has a market cap of INR 15 Cr, with a P/E ratio of 745.00 and no net profit reported.

Overview: <BR>Saptak Chem and Business Ltd operates in the trading of agricultural produce and chemicals within the micro-cap segment of the Trading & Distributors industry.<BR><BR>History: <BR>The company was incorporated on March 12, 1980, originally under the name 'Munak Chemicals Limited'. It changed its name to Saptak Chem and Business Limited in November 2017. The latest quarterly results reported are for March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 15 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 745.00 <BR>Industry P/E: 22 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -1.05 <BR>Return on Equity: -0.43% <BR>Price to Book: -6.53<BR><BR>Contact Details: <BR>Address: 3 Mohan Chamber, Beside Post Office Dakor Kheda Kheda Gujarat : 388225 <BR>Tel: +919909996192 <BR>Email: info@saptakchem.com <BR>Website: http://www.saptakchem.com

How big is Saptak Chem &?

As of 10th June, Saptak Chem & Business Ltd has a market capitalization of 15.00 Cr, with reported Net Sales of 0.00 Cr and a Net Profit loss of 0.31 Cr in the latest four quarters. The balance sheet for March 2025 shows Shareholder's Funds of -2.26 Cr and Total Assets of 0.14 Cr.

As of 10th June, Saptak Chem & Business Ltd has a market capitalization of 15.00 Cr, classifying it as a Micro Cap company.<BR><BR>In the latest four quarters, Saptak Chem & reported Net Sales of 0.00 Cr and a Net Profit loss of 0.31 Cr.<BR><BR>The latest annual reporting period for the balance sheet is March 2025, showing Shareholder's Funds of -2.26 Cr and Total Assets of 0.14 Cr.

Who are in the management team of Saptak Chem &?

The management team of Saptak Chem & includes Manthan Bhavsar (Managing Director), Chirag Nanavati, Bhoomiben Patel, and Sonal Deepalbhai Gandhi (all Independent Directors), and Meera Panchal (Company Secretary & Compliance Officer).

The management team of Saptak Chem & includes the following individuals:<BR><BR>1. **Manthan Bhavsar** - Managing Director<BR>2. **Chirag Nanavati** - Independent Director<BR>3. **Meera Panchal** - Company Secretary & Compliance Officer<BR>4. **Bhoomiben Patel** - Independent Director<BR>5. **Sonal Deepalbhai Gandhi** - Independent Director<BR><BR>If you need more information about their roles or the company, feel free to ask!

Who are the peers of the Saptak Chem &?

Saptak Chem &'s peers include Neelkanth, Ind-Agiv Commer., Yash Mgmt & Sat., UR Sugar, and others. Saptak Chem & leads with a 1-year return of 1329.00%, while UR Sugar has the lowest at -53.62%.

Peers: The peers of Saptak Chem & are Neelkanth, Ind-Agiv Commer., Yash Mgmt & Sat., Chambal Brewer, UR Sugar, Kisaan Parivar, Palm Jewels, Norris Medicines, Mihika Industrie, and Mitshi India.<BR><BR>Quality Snapshot: Below Average management risk is observed at Neelkanth, Yash Mgmt & Sat., UR Sugar, Kisaan Parivar, Palm Jewels, Mihika Industrie, and Mitshi India, while Average management risk is found at Ind-Agiv Commer. Excellent capital structure is noted at Yash Mgmt & Sat., while Good capital structure is seen at UR Sugar. The rest of the peers have Below Average or do not qualify for management risk, growth, and capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Saptak Chem & at 1329.00%, while the lowest is UR Sugar at -53.62%. Saptak Chem & significantly outperforms its peers in this regard. Additionally, peers such as Ind-Agiv Commer., UR Sugar, Kisaan Parivar, Palm Jewels, and Mihika Industrie have negative six-month returns.

Are Saptak Chem & Business Ltd latest results good or bad?

Saptak Chem & Business Ltd's latest results are concerning, showing a net loss of ₹0.12 crore in Q4 FY26 and seven years of zero revenue, alongside a negative book value of ₹-2.10 per share. The company is in critical distress with no signs of recovery, making it a high-risk investment.

The latest results for Saptak Chem & Business Ltd are quite concerning. In Q4 FY26, the company reported a net loss of ₹0.12 crore, which reflects a continuation of deepening losses. Notably, the company has not generated any revenue since FY19, marking seven consecutive years of zero sales. This operational paralysis is compounded by a negative book value of ₹-2.10 per share, indicating that the company's liabilities exceed its assets.<BR><BR>Additionally, the financial performance shows no signs of recovery, with consistent quarterly losses and no operational activity. The company's market capitalization stands at ₹13.00 crore, but this is misleading given the absence of any fundamental business operations. The lack of revenue generation, negative equity, and declining promoter holdings raise significant red flags about the company's viability.<BR><BR>Overall, the financial results indicate a company in critical distress, with no clear path to recovery or profitability. Investors should approach this situation with extreme caution.

Should I buy, sell or hold Saptak Chem & Business Ltd?

When is the next results date for Saptak Chem & Business Ltd?

The next results date for Saptak Chem & Business Ltd is 14 May 2026.

The next results date for Saptak Chem & Business Ltd is scheduled for 14 May 2026.

Why is Saptak Chem & falling/rising?

As of N/A, Saptak Chem & Business Ltd is priced at 14.75, with a notable 391.67% return over the past year, outperforming the BSE500. However, concerns arise from a flat EPS of Rs -0.19, declining promoter stakes, and negative EBITDA, indicating potential financial instability despite strong market performance.

As of N/A, Saptak Chem & Business Ltd is currently priced at 14.75, reflecting an increase of 0.28, or 1.94%. While today's price summary data is unavailable, the stock has demonstrated impressive performance over various periods, including a 391.67% return over the past year, significantly outperforming the market benchmark (BSE500), which returned only 4.72%. However, there are concerns as the company reported a flat EPS of Rs -0.19 for the quarter ending September 25, and its profits have not increased despite the high returns. Additionally, promoter confidence appears to be waning, with a 3.73% reduction in their stake, which may indicate a lack of faith in the company's future prospects.<BR><BR>In the broader market context, Saptak Chem's short-term return of 10.07% over the past week stands in stark contrast to the Sensex, which has declined by 1.38%. This strong performance relative to the benchmark suggests that investor interest in Saptak Chem remains robust despite the underlying risks, such as negative EBITDA and declining promoter stakes. The company's ability to generate substantial returns over the longer term, coupled with recent price increases, indicates a complex situation where positive market performance is tempered by significant financial concerns.

How has been the historical performance of Saptak Chem &?

Saptak Chem & has experienced a significant decline in financial performance from 2019 to 2025, with net sales dropping to zero and increasing losses, resulting in negative reserves and shareholder funds. Overall, the company has shown a consistent downward trend in key financial metrics.

Answer:<BR>The historical performance of Saptak Chem & shows a significant decline in financial metrics over the years, particularly from 2019 to 2025.<BR><BR>Breakdown:<BR>Saptak Chem & experienced a notable drop in net sales, with figures decreasing from 3.57 Cr in March 2019 to 0.00 Cr in March 2025. Total operating income followed a similar trend, peaking at 3.57 Cr in March 2019 and falling to 0.00 Cr by March 2025. The company's total expenditure, excluding depreciation, also fluctuated, with a high of 3.50 Cr in March 2019 and a low of 0.09 Cr in March 2025. Operating profit (PBDIT) turned negative, moving from a profit of 0.07 Cr in March 2019 to a loss of 0.09 Cr in March 2025. Profit before tax and profit after tax mirrored this decline, with losses reported in the last two years. The company's reserves have been negative since March 2020, reaching -12.99 Cr in March 2025. Shareholder's funds remained negative, indicating a deteriorating financial position, while total liabilities decreased from 1.59 Cr in March 2019 to 0.16 Cr in March 2024. Overall, Saptak Chem & has seen a consistent decline in performance metrics, culminating in zero revenue and increasing losses in recent years.

Is Saptak Chem & overvalued or undervalued?

As of September 23, 2025, Saptak Chem & is considered overvalued with a PE ratio of 0.92 and negative financial metrics, despite a 216.97% stock return over the past year, contrasting sharply with its peers.

As of 23 September 2025, the valuation grade for Saptak Chem & has moved from risky to does not qualify, indicating a significant deterioration in its valuation outlook. The company appears to be overvalued based on its current financial metrics, including a PE ratio of 0.92, an EV to EBIT of -3.23, and an ROCE of -9.00%. These figures suggest that the company's earnings and capital efficiency are not aligned with its market price.<BR><BR>In comparison to its peers, Saptak Chem & stands out with a PE ratio of 0.92, while Coromandel International has a PE of 33.48 and Chambal Fertilizers shows a PE of 12.31. This stark contrast highlights Saptak Chem &'s unfavorable position in the market. Additionally, the company has shown a remarkable return of 216.97% over the past year, significantly outperforming the Sensex, which declined by 3.33% during the same period. However, despite this impressive stock performance, the underlying financial ratios indicate that Saptak Chem & is currently overvalued.

What is the technical trend for Saptak Chem &?

As of June 5, 2025, Saptak Chem's trend is mildly bullish in the short term, but longer-term indicators show mixed signals with bearish tendencies on the weekly and monthly charts.

As of 5 June 2025, the technical trend for Saptak Chem & has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating a positive trend. However, the weekly MACD is bearish and the monthly MACD is mildly bearish, suggesting some weakness in the longer time frames. The KST remains bullish on both weekly and monthly charts, which provides some strength to the overall outlook. The Bollinger Bands show a mildly bearish trend on the weekly, while the Dow Theory indicates a mildly bearish stance on the weekly and no trend on the monthly. Overall, the indicators present a mixed picture, with short-term bullishness countered by longer-term bearish signals.

Who are the top shareholders of the Saptak Chem &?

The top shareholders of Saptak Chem & include Alpha Antibiotics Limited with 12.58%, and Parag Dinesh Sanghvi (HUF) at 8.37%. Individual investors hold 75.01%, with no pledged promoter holdings or involvement from mutual funds or foreign institutional investors.

The top shareholders of Saptak Chem & include Alpha Antibiotics Limited, which holds the highest promoter stake at 12.58%. The highest public shareholder is Parag Dinesh Sanghvi (HUF), with a holding of 8.37%. Additionally, individual investors collectively hold a significant portion of 75.01%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) involved.

Has Saptak Chem & declared dividend?

No Dividend History Available